Drug Trial Radar · NCT07090954
A Study of GR1803 Injection in Combination With Anti-CD38 Monoclonal Antibody for the Treatment of Participants With Multiple Myeloma
Last checked: Nov 19, 2026Latest source record: Jul 29, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
32
Planned (sponsor's estimate)
Start
Aug 31, 2025
Primary completion
Jul 31, 2026
Study completion Jan 31, 2030
Sponsor
- Lead sponsor
- Genrix (Shanghai) Biopharmaceutical Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Jul 29, 2025
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Not applicable (single group)
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to identify recommended Phase 3 doses (RP3D) for treatment combination (GR1803 injection plus anti-CD38 monoclonal antibody) and to characterize the efficacy of RP3D for the treatment combination.
Conditions
- Multiple Myeloma
Interventions
GR1803 injectionDrug
Participants will receive GR1803 injection.
Anti-CD38 Monoclonal AntibodyDrug
Participants will receive anti-CD38 monoclonal antibody.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Dose Escalation: Number of Participants With Dose Limiting Toxicity (DLT)Time frame: Up to 2 Years
- Dose escalation: Number of Participants With Adverse Events and Serious Adverse EventsTime frame: Up to 2 Years
- Dose expansion: Overall Response RateTime frame: Up to 2 Years
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
Shanghai Fourth People's Hospital Affiliated with Tongji University
Shanghai, China
The First Affiliated Hospital of Xi'an Jiaotong University
Xi'an, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.